elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Natalizumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Natalizumab
RIS
0.000
(Research Intensity Score)
Papers
53
Top papers
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
2025 · 15 citations
Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis
2020 · 118 citations
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
2018 · 219 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
2025 · 10 citations
Newest papers
Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study
2026 · 2 citations
Lifestyle Modification Rehabilitation and Pharmacotherapy in Multiple Sclerosis
2026
Possible Contribution of Multiple Sclerosis Pathology to Treatment‐Resistant Schizophrenia: A Case Study
2026
Predictors of Multiple Sclerosis After Clinically Isolated Syndrome: A Systematic Review and Meta‐Analysis
2026
Highly active multiple sclerosis - An important, yet inaccurate concept
2026 · 1 citations
A sample from the 53 top papers behind Natalizumab.
Create a free account to browse them all →
Natalizumab's history
Research intensity over time
Explore Natalizumab's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Natalizumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link